# Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion

Study · id `cardio:ct-nct04166331` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04166331](<https://clinicaltrials.gov/study/NCT04166331>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04166331

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

## Technical summary

Registry record NCT04166331. Randomized; triple masking; primary purpose treatment. Start 2020-09-20 (actual); primary completion 2025-07-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 136 participants (enrolled count; ClinicalTrials.gov record NCT04166331, source copy `cardio:ctgov-nct04166331-2025-11-21`, retrieved 2026-10-31)
- Started: 2020-09-20 (actual) (ClinicalTrials.gov record NCT04166331, source copy `cardio:ctgov-nct04166331-2025-11-21`, retrieved 2026-10-31)
- Primary completion: 2025-07-01 (actual) (ClinicalTrials.gov record NCT04166331, source copy `cardio:ctgov-nct04166331-2025-11-21`, retrieved 2026-10-31)
- Completion: 2025-07-01 (actual) (ClinicalTrials.gov record NCT04166331, source copy `cardio:ctgov-nct04166331-2025-11-21`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT04166331, source copy `cardio:ctgov-nct04166331-2025-11-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04166331-2025-11-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
- Acronym: ADAPT
- Condition: Sepsis
- Condition: Cardiomyopathies
- Condition: Hypoperfusion
- Condition: Left Ventricular Systolic Dysfunction
- Intervention (Drug): Placebos
- Intervention (Drug): Dobutamine
- Lead sponsor: University Hospital, Limoges
- Lead sponsor class: OTHER
- Collaborator: Centre d'Investigation Clinique 1415
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry intervention name matches this record: Dobutamine (`cardio:dobutamine`)

## Provenance

Content hash: 08b9d02a1c1d48e3496a38a203f5dd277bc862f1215a9966f222c7912282c3f0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
